0000914475-24-000090.txt : 20240315
0000914475-24-000090.hdr.sgml : 20240315
20240315171530
ACCESSION NUMBER: 0000914475-24-000090
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240313
FILED AS OF DATE: 20240315
DATE AS OF CHANGE: 20240315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Delaet Ingrid
CENTRAL INDEX KEY: 0001965808
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 24755937
MAIL ADDRESS:
STREET 1: C/O NEUROCRINE BIOSCIENCES, INC.
STREET 2: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
wk-form4_1710537319.xml
FORM 4
X0508
4
2024-03-13
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001965808
Delaet Ingrid
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Regulatory Officer
1
Common Stock
2024-03-13
4
M
0
3000
106.02
A
10507
D
Common Stock
2024-03-13
4
S
0
3000
140.1398
D
7507
D
Non-Qualified Stock Option
106.02
2024-03-13
4
M
0
3000
106.02
D
2031-02-01
Common Stock
3000
4367
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Option granted February 1, 2021 and vests at 25% upon first anniversary (February 1, 2022) and remaining 75% vesting in 36 equal monthly installments beginning on March 1, 2022.
/s/ Darin Lippoldt, Attorney-in-Fact
2024-03-15